Stockreport

Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025 [Yahoo! Finance]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF Wainwright's Brandon Folkes reaffirmed a Buy on CorMedix Inc. (NASDAQ:CRMD), citing strong DefenCath-driven revenue, Melinta acquisition synergies, and multiple growth c [Read more]